Skip to main content
BLTE logo

Belite Bio, Inc (BLTE) Stock: Price, Forecast & Analyst Target

Belite Bio, Inc (BLTE) — MoonshotScore 64/100 (Fair band), calculated Nov 18, 2026. Price $127.38 (-15.65%), as of the Nov 20, 2026 trading session; market cap $5.17B. Expected results Mar 1, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$127.38 −$23.64 (-15.65%) Market Cap $5.17B

Belite Bio, Inc · BLTE · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Belite Bio is a clinical-stage drug developer pursuing oral therapies for retinal disease, led by a candidate designed to limit the buildup of damaging vitamin A metabolites in ocular tissue. It does not yet sell a product, so rising research expense and widening losses describe development intensity rather than customer demand. Clinical validation must ultimately convert that spending into a commercial medicine for the forecast revenue path to become credible.

Price as of Nov 20, 2026

Key Statistics

64 of 100

MoonshotScore v2 · Belite Bio (BLTE)

Fair
Business Quality Average (49)
Financial Safety Fortress (98)
Valuation Full (54)
Growth Durability Shrinking (7)
Momentum Rising (79)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet, but stalling growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Shrinking; Momentum: Rising.

  • quarterly revenue $0 (Q2 FY2026, quarter ended Jun 2026)
  • EPS beat 4 of the last 8 reports
  • ROE -17.0% · ROA -14.0% · current ratio 33.56 · earnings yield -1.7% · free-cash-flow yield -0.0%

Holding back: soft growth

Helping: balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for BLTE (58 recorded, newest six shown)
RecordedScoreBand
80Strong
67Strong
67Strong
64Fair
64Fair
64Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$127.38
Change on the day-15.65%
52-week range$105.88–$200.00
Market capitalisation$5.17B—
Shares traded on the day1.04M
Beta (volatility vs the S&P 500)-1.19

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $88, high $194, latest $127. 4 reported quarters marked, 4 above and 0 below the recorded estimate. $194 $88 high $194 Mar 2, 2026 · Earnings results · reported above the recorded estimate · close $1901May 20, 2026 · Earnings results · reported above the recorded estimate · close $1372Aug 12, 2026 · Earnings results · reported above the recorded estimate · close $1633Nov 12, 2026 · Earnings results · reported above the recorded estimate · close $1644 Oct 17, 2025 Nov 20, 2026 · $127 $88Oct 17, 2025$106Oct 31, 2025$117Nov 14, 2025$137Nov 28, 2025$141Dec 12, 2025$155Dec 26, 2025$158Jan 9, 2026$165Jan 23, 2026$188Feb 6, 2026$181Feb 20, 2026$173Mar 6, 2026$155Mar 20, 2026$170Apr 2, 2026$165Apr 17, 2026$155May 1, 2026$143May 15, 2026$144May 29, 2026$138Jun 12, 2026$149Jun 26, 2026$149Jul 10, 2026$153Jul 24, 2026$163Aug 7, 2026$161Aug 21, 2026$194Sep 4, 2026$171Sep 18, 2026$160Oct 2, 2026$143Oct 16, 2026$155Oct 30, 2026$164Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

  1. Next results dueProvider estimate
How to read these dates

Estimated dates can change.

What to watch next

Other perspectives

Council score for Belite Bio (BLTE): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Strong
Valuation Neutral
Growth Durability Negative
Momentum Moderate

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 12, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 12, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Belite Bio (BLTE), and what does it report?

Short answer · as of

Belite Bio’s main program targets Stargardt disease and atrophic age-related macular degeneration through an investigational oral therapy that modulates vitamin A delivery to the eye.

A separate preclinical oral program extends the platform toward liver and metabolic disorders.

Reported revenue remains absent. The income statement therefore measures research progress indirectly through development expense, administrative cost and net loss, while the compact workforce reinforces the profile of a focused drug developer rather than a commercial pharmaceutical operation.

2 · Latest results

What do the latest results show for Belite Bio (BLTE)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $0.

The latest results extend a clear pattern: research expense increased, the operating loss widened and the net loss deepened, while administrative expense eased slightly from the preceding period. Recent earnings have nevertheless been less negative than consensus expected, showing better expense outcomes relative to forecasts without changing the precommercial status of the business.

With the retinal candidate in late-stage trials, research spending is the most direct reported link between pipeline advancement and the worsening operating result. The figures support an expense-driven change, not a revenue-driven deterioration, because commercial sales remain absent.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · EPS vs estimate
Above estimate Nov 12, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Nov 12, 2026Not availableNot available−$0.6000−$0.7863
Aug 12, 2026Not availableNot available−$0.7000−$0.7300
May 20, 2026Not availableNot available−$0.3400−$0.6000
Mar 2, 2026Not available$16.67M−$0.3800−$0.5600
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$0-$28M-$0.71 (diluted)
Q1 FY2026$0-$27M-$0.68 (diluted)
Q4 FY2025$0-$25M-$0.76 (diluted)
Sep 2025$0-$22M-$0.65 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Belite Bio (BLTE)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Reported debt is absent, liquidity ratios are exceptionally high and the distress screen appears strong. Yet the latest cash and investment balances are nil after earlier observations showed substantial liquidity, while the calculated cash decline spans the full reported window. That uneven balance-sheet picture does not support a dependable runway conclusion on its own.

An isolated operating cash-flow observation appears close to neutral, but recurring net losses and accelerating research expense show that Belite Bio is not economically self-funding. Institutional participation increased modestly, while recent insider activity consisted entirely of sales rather than purchases; neither observation explains the clinical outlook, but each matters if external capital becomes important.

Data-derived red flags

  • Negative return on equity (-17.0%) — the business is not currently generating profit on shareholder capital.
  • Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Belite Bio (BLTE)?

Short answer · as of

The next earnings report is expected on Mar 1, 2027.

The scheduled earnings update should be read for research spending, administrative discipline and whether the reported cash balance becomes consistent with the earlier liquidity history. A smaller loss relative to expectations would matter less than evidence that late-stage work is advancing without another sharp increase in the expense base.

Longer-range forecasts assume a transition from absent revenue and negative earnings to meaningful sales and profitability, but the wide forecast range signals substantial disagreement about commercialization. Progress in the retinal program is therefore the observation that must connect current spending with those estimates.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Belite Bio compare with its peers?

Short answer

Belite Bio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Belite Bio differs from a diversified commercial biotechnology company because its value is concentrated in clinical validation rather than a portfolio of marketed products. Its defining feature is an oral approach to retinal disease that aims to control vitamin A metabolite accumulation, paired with an earlier program applying related biology to liver and metabolic conditions.

The compact workforce and absent revenue place the company among focused precommercial developers, but the analyst forecast spread shows unusually divergent commercialization assumptions. That makes comparison through current sales multiples less informative than comparing clinical progress, spending intensity and the durability of funding.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Same industry, near in market value$93.89 Nov 20, 2026$7.38B98 5-pillar Nov 18, 2026
ADMA Biologics, Inc. (ADMA) Named competitor$13.17 Nov 20, 2026$2.92B97 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$63.62 Nov 20, 2026$6.96B91 5-pillar Nov 18, 2026
Arcutis Biotherapeutics, Inc. (ARQT) Named competitor$26.36 Nov 20, 2026$3.33B89 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$39.91 Nov 20, 2026$4.37B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$17.58 Nov 20, 2026$5.04B83 5-pillar Nov 18, 2026
Enliven Therapeutics, Inc. (ELVN) Same industry, near in market value$46.53 Nov 20, 2026$3.42B72 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$286.85 Nov 20, 2026$5.74B71 5-pillar Nov 18, 2026
ACADIA Pharmaceuticals Inc. (ACAD) Named competitor$17.59 Nov 19, 2026$3.04B68 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.61 Nov 20, 2026$4.78B67 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.81 Nov 20, 2026$6.50B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$119.52 Nov 20, 2026$5.04B66 5-pillar Nov 18, 2026
Belite Bio (BLTE) — this page$127.38$5.17B64

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$206.00 – $303.00
Consensus target
$245.17
Median target
$237.50

Consensus record · Captured .

Measured against a quoted price of $127.38 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 29, 2026

Transactions
67
Identified insiders
4
Purchases
0
Sales
63
Other transactions
4

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held BLTE in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Duquesne Family OfficeStanley DruckenmillerQ3 20260.40%$18.02MHeld, unchanged

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Belite Bio (BLTE)?

Read these with our analysis →

What Investors Ask About Belite Bio (BLTE) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

What is Belite Bio trying to change in Stargardt disease?

Its oral retinal candidate is designed to modulate vitamin A delivery and prevent harmful metabolites from accumulating in ocular tissue. Clinical validation carries unusual weight because the company has no commercial revenue while research expense continues to rise.

Why can Belite Bio beat earnings expectations while remaining precommercial?

An earnings beat can result from a loss that is less negative than analysts expected, without any product sales. Recent results cleared consensus expectations while the income statement continued to show absent revenue and substantial development expense.

Does Belite Bio’s reported liquidity establish a dependable trial runway?

The liquidity picture is internally uneven: leverage is absent and liquidity ratios are strong, but the latest cash records are nil after earlier substantial balances. The calculated decline therefore deserves attention alongside future cash disclosures and the rising loss rate.

How does Belite Bio’s liver program fit beside its retinal program?

The earlier-stage oral program targets retinol-binding biology across liver and metabolic disorders, adding scientific breadth beside the late-stage retinal candidate. Financially, the company still reports as a precommercial developer, so that breadth has not produced a separate revenue stream.

What is the BLTE stock price today?

The last price recorded for Belite Bio, Inc (BLTE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the BLTE price target?

The analyst consensus price target for Belite Bio, Inc (BLTE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 35 figures on this page — 1 from SEC filings and earnings calls, 28 from Financial Modeling Prep (FMP), 4 with no recorded source, 1 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Analyst revenue and earnings estimates (average)
  • 1. What is Belite Bio (BLTE), and what does it report?: Business description; Employees; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Belite Bio (BLTE)?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters
  • 3. What are the financial strengths and risks for Belite Bio (BLTE)?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Operating cash flow by quarter (USD millions); Quarterly income statement (USD thousands); Trailing twelve-month ratio set; Distress and quality screens; Institutional ownership (13F); Insider transactions, last 180 days
  • 4. What should you watch next at Belite Bio (BLTE)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Cash and short-term investments over time (USD millions); Business description
  • 5. How does Belite Bio compare with its peers?: Business description; Employees; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Analyst revenue and earnings estimates (average); Trailing twelve-month ratio set
  • FAQ: What is Belite Bio trying to change in Stargardt disease?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: Why can Belite Bio beat earnings expectations while remaining precommercial?: Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • FAQ: Does Belite Bio’s reported liquidity establish a dependable trial runway?: Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Trailing twelve-month ratio set
  • FAQ: How does Belite Bio’s liver program fit beside its retinal program?: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.